MRI/PET scans reveal racial disparities in Alzheimer’s disease biomarkers

Racial differences in Alzheimer’s disease biomarkers may point to possible race-dependent biological mechanisms that contribute to how the disease is expressed, according to research published online Jan. 7 in JAMA Neurology.  

The findings suggest the evaluation of molecular biomarkers for Alzheimer’s disease should be adjusted for race, as African American patients were found to have lower levels of tau—a key biomarker used to identify the disease, according to John C. Morris, MD, of the Knight Alzheimer Disease Research Center (ADRC) at the Washington University School of Medicine in St. Louis, Missouri, and colleagues.  

A total of 1,255 participants (56 percent women, 14 percent African American, average age 71 years) were recruited and completed brain…

Read More